{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products#webpage",
"url": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products",
"name": "Combined advanced therapy medicinal products",
"description": "This Fortrea white paper explores advanced therapy medicinal products and the European regulatory pathways affecting advanced therapy development programs. The content focuses on advanced therapy medicinal products, ATMP classification, European regulatory pathways, regulatory requirements, and development considerations associated with advanced therapy programs. The white paper highlights considerations related to ATMP categorization, regulatory interpretation, evolving European regulatory expectations, and planning approaches affecting advanced therapy medicinal product development environments. Fortrea discusses regulatory perspectives designed to support advanced therapy medicinal product planning, improve understanding of European regulatory pathways, and address development considerations associated with evolving ATMP programs. By integrating regulatory pathway understanding with ATMP classification and development considerations, the white paper provides insights into advanced therapy medicinal products and European regulatory pathways across advanced therapy research and development environments."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Combined advanced therapy medicinal products",
"item": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/combined-advanced-therapy-medicinal-products#webpage"
},
"headline": "Advanced Therapy Medicinal Products and European Regulatory Pathways | Fortrea White Paper",
"description": "This Fortrea white paper explores advanced therapy medicinal products and the European regulatory pathways affecting advanced therapy development programs. The content focuses on advanced therapy medicinal products, ATMP classification, European regulatory pathways, regulatory requirements, and development considerations associated with advanced therapy programs. The white paper highlights considerations related to ATMP categorization, regulatory interpretation, evolving European regulatory expectations, and planning approaches affecting advanced therapy medicinal product development environments. Fortrea discusses regulatory perspectives designed to support advanced therapy medicinal product planning, improve understanding of European regulatory pathways, and address development considerations associated with evolving ATMP programs. By integrating regulatory pathway understanding with ATMP classification and development considerations, the white paper provides insights into advanced therapy medicinal products and European regulatory pathways across advanced therapy research and development environments.",
"genre": "White Paper",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-21",
"dateModified": "2024-10-21",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/Whitepaper_0051_Combined%20ATMPS_0524_HIghRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}